NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free CDTX Stock Alerts $12.51 -0.17 (-1.34%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$11.75▼$13.2050-Day Range$10.25▼$23.2052-Week Range$10.00▼$29.60Volume53,967 shsAverage Volume51,964 shsMarket Capitalization$57.05 millionP/E RatioN/ADividend YieldN/APrice Target$71.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cidara Therapeutics alerts: Email Address Cidara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside469.5% Upside$71.25 Price TargetShort InterestHealthy0.18% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.40Based on 10 Articles This WeekInsider TradingSelling Shares$40,468 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($13.07) to $12.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.44 out of 5 starsMedical Sector571st out of 5,430 stocksBiological Products, Except Diagnostic Industry46th out of 903 stocks 3.6 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the outstanding shares of Cidara Therapeutics have been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently decreased by 95.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cidara Therapeutics is -0.85. Previous Next 2.4 News and Social Media Coverage News SentimentCidara Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for CDTX on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat Follows7 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $40,468.00 in company stock.Percentage Held by InsidersOnly 7.43% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to grow in the coming year, from ($13.07) to $12.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Cidara Therapeutics Stock (NASDAQ:CDTX)Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More CDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDTX Stock News HeadlinesApril 29, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Cidara Therapeutics, Inc. Decreased by Analyst (NASDAQ:CDTX)April 28, 2024 | americanbankingnews.comBrokerages Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) Price Target at $71.25May 3, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 27, 2024 | americanbankingnews.comCidara Therapeutics (NASDAQ:CDTX) PT Raised to $25.00April 27, 2024 | americanbankingnews.comWBB Securities Reiterates "Strong-Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX)April 27, 2024 | americanbankingnews.comCidara Therapeutics, Inc. (NASDAQ:CDTX) to Post FY2025 Earnings of $12.63 Per Share, HC Wainwright ForecastsApril 26, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 26, 2024 | finance.yahoo.comCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024May 3, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 26, 2024 | americanbankingnews.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up Following Analyst UpgradeApril 25, 2024 | businesswire.comCDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTXApril 24, 2024 | msn.comCidara Therapeutics shares surge 30% after reacquiring flu treatmentApril 24, 2024 | marketwatch.comCidara Therapeutics To Sell Candidiasis Treatment, Re-acquire Flu AssetApril 24, 2024 | msn.comCidara stock rallies amid $240M private placement, drug updateApril 24, 2024 | globenewswire.comCidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 MillionApril 24, 2024 | globenewswire.comCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC PipelineApril 24, 2024 | americanbankingnews.comCidara Therapeutics' (CDTX) Overweight Rating Reaffirmed at Cantor FitzgeraldApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 23, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | investorplace.comCDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023April 22, 2024 | msn.comWhy Cidara Therapeutics (CDTX) Stock Is FallingApril 22, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Receipt of Nasdaq Delinquency NoticeApril 22, 2024 | globenewswire.comCidara Therapeutics Announces Reverse Stock SplitApril 14, 2024 | seekingalpha.comCDTX Cidara Therapeutics, Inc.April 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program DevelopmentsApril 7, 2024 | investing.comCidara Therapeutics reveals promising cancer therapy dataSee More Headlines Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/03/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CDTX CUSIPN/A CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Target$71.25 High Stock Price Target$120.00 Low Stock Price Target$25.00 Potential Upside/Downside+466.8%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,930,000.00 Net Margins-33.19% Pretax Margin-35.19% Return on Equity-201.62% Return on Assets-30.28% Debt Debt-to-Equity RatioN/A Current Ratio0.90 Quick Ratio0.81 Sales & Book Value Annual Sales$63.90 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($1.82) per share Price / Book-6.91Miscellaneous Outstanding Shares4,560,000Free Float4,223,000Market Cap$57.32 million OptionableOptionable Beta1.11 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Jeffrey L. Stein Ph.D. (Age 69)President, CEO & Executive Director Comp: $873.25kDr. Preetam Shah M.B.A. (Age 51)Ph.D., CFO, Chief Business Officer & Principal Accounting Officer Comp: $577.85kDr. Taylor Sandison (Age 52)Chief Medical Officer Comp: $632.05kDr. Kevin M. Forrest Ph.D. (Age 47)Founder and Chief Strategy Officer Comp: $333.31kMr. Shane M. Ward (Age 49)COO & Chief Legal Officer Ms. Allison Lewis CCPSPHR, Senior Vice President of People & CultureDr. Leslie Tari Ph.D. (Age 57)Chief Scientific Officer Comp: $845.1kMs. Laura A. NavaltaSenior Vice President of Clinical OperationsDr. Nicole Davarpanah J.D.M.D., Senior VP of Translational Research & DevelopmentMore ExecutivesKey CompetitorsAVROBIONASDAQ:AVROGenenta ScienceNASDAQ:GNTAEntera BioNASDAQ:ENTXAligos TherapeuticsNASDAQ:ALGSLENZ TherapeuticsNASDAQ:LENZView All CompetitorsInsiders & InstitutionsCallan Capital LLCSold 8,293 shares on 5/3/2024Ownership: 2.087%Leslie TariSold 1,051 sharesTotal: $14,083.40 ($13.40/share)Preetam ShahSold 946 sharesTotal: $12,676.40 ($13.40/share)Shane WardSold 1,023 sharesTotal: $13,708.20 ($13.40/share)Leslie TariSold 923 sharesTotal: $17,537.00 ($19.00/share)View All Insider TransactionsView All Institutional Transactions CDTX Stock Analysis - Frequently Asked Questions Should I buy or sell Cidara Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CDTX shares. View CDTX analyst ratings or view top-rated stocks. What is Cidara Therapeutics' stock price target for 2024? 4 analysts have issued twelve-month price objectives for Cidara Therapeutics' stock. Their CDTX share price targets range from $25.00 to $120.00. On average, they expect the company's stock price to reach $71.25 in the next year. This suggests a possible upside of 469.5% from the stock's current price. View analysts price targets for CDTX or view top-rated stocks among Wall Street analysts. How have CDTX shares performed in 2024? Cidara Therapeutics' stock was trading at $15.88 on January 1st, 2024. Since then, CDTX shares have decreased by 21.2% and is now trading at $12.51. View the best growth stocks for 2024 here. Are investors shorting Cidara Therapeutics? Cidara Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 8,200 shares, a decline of 95.8% from the March 31st total of 195,400 shares. Based on an average daily trading volume, of 40,600 shares, the days-to-cover ratio is currently 0.2 days. View Cidara Therapeutics' Short Interest. When is Cidara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CDTX earnings forecast. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($7.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.20) by $0.20. The biotechnology company had revenue of $7.08 million for the quarter, compared to analysts' expectations of $3.62 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 201.62% and a negative net margin of 33.19%. When did Cidara Therapeutics' stock split? Cidara Therapeutics shares reverse split before market open on Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX). When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Callan Capital LLC (2.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brady Johnson, Jeffrey Stein, Leslie Tari, Paul Daruwala, Preetam Shah, Shane Ward, Taylor Sandison and Timothy R Franson. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDTX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
